Gut Microbiome

Akkermansia muciniphila attenuates intervertebral disc degeneration via extracellular vesicle-mediated delivery of the effector protein B2UKX5.

TL;DR

Akkermansia muciniphila attenuates intervertebral disc degeneration via extracellular vesicle-mediated delivery of the effector protein B2UKX5, establishing a novel gut-disc axis.

Key Findings

Mendelian randomization and clinical cohort analysis identified a causal inverse relationship between Akkermansia muciniphila abundance and IVDD risk.

  • Mendelian randomization was used to establish causality, not just correlation, between Akk abundance and IVDD risk.
  • Reduced fecal Akk levels correlated with increased IVDD severity in the clinical cohort.
  • The relationship was described as a 'causal inverse relationship,' suggesting higher Akk abundance is associated with lower IVDD risk.

Akkermansia muciniphila protected against IVDD in microbiota-depleted mice, and this protection was abolished by pharmacologic inhibition of extracellular vesicle secretion.

  • Experiments were conducted in microbiota-depleted (likely germ-free or antibiotic-treated) mice to isolate the effect of Akk.
  • Pharmacologic inhibition of EV secretion eliminated the protective effect of Akk, implicating EVs as the primary mediator of protection.
  • This finding mechanistically links Akk's gut-disc protective effect specifically to its EV secretion.

Akk-derived extracellular vesicles (Akk-EVs) recapitulated the protective benefits of Akk across multiple mouse models of IVDD.

  • Three distinct mouse models were used: natural aging, tail needle puncture, and bipedal standing models.
  • Akk-EVs reproduced the protective effects seen with live Akk administration across all three models.
  • Control bacterium Escherichia coli and its EVs did not confer similar protection, indicating specificity of the Akk-EV effect.

Proteomics and functional validation identified B2UKX5 as a key effector protein enriched in Akk-derived extracellular vesicles.

  • Proteomic analysis of Akk-EVs was used to identify candidate effector proteins.
  • B2UKX5 was identified as specifically enriched in Akk-EVs compared to control conditions.
  • Functional validation confirmed B2UKX5's role as the key mediator of Akk-EV effects on disc health.

Recombinant B2UKX5 attenuated IVDD in vivo and regulated critical pathways for disc homeostasis.

  • Administration of recombinant B2UKX5 protein was sufficient to attenuate IVDD in animal models.
  • Transcriptomic profiling of microdissected nucleus pulposus and annulus fibrosus tissues revealed regulated pathways.
  • Key pathways regulated by B2UKX5 included collagen synthesis, extracellular matrix remodeling, and chromatin silencing.
  • Microdissection of distinct disc tissue compartments (nucleus pulposus and annulus fibrosus) allowed tissue-specific transcriptomic analysis.

Circulating and intervertebral disc tissue levels of Akk-EVs and B2UKX5 were negatively correlated with IVDD severity in clinical samples.

  • Both Akk-EVs and B2UKX5 levels were measured in circulation and in intervertebral disc tissues from clinical samples.
  • Higher levels of Akk-EVs and B2UKX5 were associated with lower IVDD severity.
  • This clinical correlation validated the mechanistic findings from animal models in human subjects.

What This Means

This research suggests that a specific gut bacterium, Akkermansia muciniphila (Akk), plays a protective role against intervertebral disc degeneration (IVDD), a major cause of low back pain. Using genetic analysis techniques (Mendelian randomization) and patient data, the researchers found that people with lower amounts of this bacterium in their gut had a higher risk of disc degeneration. Experiments in mice confirmed that Akk reduces disc degeneration, and that this protection works through tiny particles the bacteria release called extracellular vesicles (EVs). When EV release was blocked, the bacteria's protective effects disappeared. The researchers traced the mechanism further to a specific protein called B2UKX5 that is packed into these bacterial vesicles. These vesicles appear to travel from the gut to the spinal discs, where B2UKX5 helps maintain disc health by regulating collagen production, tissue structure maintenance, and gene regulation processes. Giving mice a lab-made version of B2UKX5 alone was also enough to reduce disc degeneration. Importantly, patients with more severe disc degeneration had lower levels of both Akk-EVs and B2UKX5 in their blood and disc tissues, consistent with the animal findings. This research establishes what the authors call a 'gut-disc axis,' suggesting that the health of spinal discs may be influenced by gut bacteria. This could have implications for understanding why some people develop disc degeneration and low back pain, and points to Akkermansia muciniphila, its extracellular vesicles, and the protein B2UKX5 as potential new targets for preventing or treating this common and disabling condition.

Have a question about this study?

Citation

Guan Z, Li X, Chen Y, Zhu S, Wen J, Zhou H, et al.. (2026). Akkermansia muciniphila attenuates intervertebral disc degeneration via extracellular vesicle-mediated delivery of the effector protein B2UKX5.. Bone research. https://doi.org/10.1038/s41413-026-00541-5